34 completed, 11 unknown, 9 recruiting, 9 terminated. 79 Phase 2, 13 Phase 3, 9 Phase 1.
Follow Hypopigmentation: new trials by email Literature Review of Hypopigmentation trials Research Report on Hypopigmentation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo TEV-53408 Dose A, TEV-53408 Dose B, Placebo - Vitiligo | Phase 2 / Phase 3 | Not yet recruiting | Teva Branded Pharmaceutical Products R&D LLC | 1020 | 2026-11-16 | 2026-11-05 |
| A Clinical Trial of Multiple Doses of GR2301 Injection in Participants With Vitiligo. GR2301 injection, Placebo - Vitiligo | Phase 2 | Not yet recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 120 | 2026-11-01 | 2026-11-10 |
| Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL - Vitiligo Vulgaris | Phase 2 / Phase 3 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 5 | 2026-09-01 | 2026-06-05 |
| Study of D-2570 in Subjects With Non-Segmental Vitiligo D-2570 Dose 1, D-2570 Dose 2, Placebo - Vitiligo, Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | InventisBio Co., Ltd | 160 | 2026-06-11 | 2026-07-15 |
| A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo GR2301 injection, Placebo - Vitiligo | Phase 1 / Phase 2 | Not yet recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 116 | 2026-06-01 | 2026-06-15 |
| A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo LY4005130, Placebo - Vitiligo, Non-Segmental Vitiligo (NSV) | Phase 2 | Recruiting | Eli Lilly and Company | 66 | 2026-04-14 | 2026-11-04 |
| Topical Delgocitinib for Facial Vitiligo Delgocitinib cream - Vitiligo | Phase 2 | Active not recruiting | Lone Skov | 12 | 2026-04-08 | 2026-09-15 |
| Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Intravenous Infusion, Oral Prednisone, Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Local Injection - Vitiligo, Mesenchymal Stem Cells | Phase 1 / Phase 2 | Not yet recruiting | Xijing Hospital | 96 | 2026-04-01 | 2026-04-09 |
| Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study NB-UVB combined with microneedling and topical 10% secretome, receives NB-UVB combined with intradermal secretome injection, NB-UVB alone - Vitiligo | Phase 2 / Phase 3 | Not yet recruiting | Yohanes Firmansyah, dr, MH, MM | 150 | 2026-03-18 | 2026-04-03 |
| Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo LITFULO, LITFULO and UVB - Vitiligo | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 56 | 2026-03-12 | 2026-05-20 |
| A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo GIA632, Placebo - Non-segmental Vitiligo | Phase 2 | Recruiting | Novartis Pharmaceuticals | 210 | 2026-03-09 | 2026-11-09 |
| Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo Melanotan II (MT-II), Placebo, Narrowband UV-B (NB-UVB) phototherapy - NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable) | Phase 2 | Recruiting | Hudson Biotech | 60 | 2026-02-02 | 2026-02-27 |
| Gingival Hyperpigmentation Treatment Vitamin c and glutathione, Surgical depigmentation - Gingival Pigmentation, Depigmentation | Phase 2 | Recruiting | Cairo University | 30 | 2025-08-01 | 2026-05-19 |
| Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment physician-selected treatment, Regorafenib + Envafolimab - GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation | Phase 2 | Recruiting | Jian Li | 100 | 2025-07-14 | 2026-04-30 |
| 0.005% Latanoprost Gel for Nonsegmental Vitiligo 0.005% latanoprost gel, 0.1% mometasone furoate cream - Vitiligo - Macular Depigmentation | Phase 2 | Not yet recruiting | Universitas Padjadjaran | 10 | 2025-07-01 | 2025-06-11 |
| Evaluating the Efficacy and Safety of Metformin in Vitiligo Metformin Hydrochloride - Vitiligo | Phase 2 | Withdrawn | University of Massachusetts, Worcester | 2025-07-01 | 2024-09-24 | |
| A Trial of SHR0302Base in Patients With Vitiligo SHR0302Base gel, SHR0302Base gel placebo - Vitiligo | Phase 2 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 155 | 2025-02-13 | 2026-01-15 |
| Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus Ruxolitinib Cream 1.5%, Aqueous cream - Vitiligo | Phase 2 / Phase 3 | Recruiting | Hospital Authority, Hong Kong | 20 | 2024-11-29 | 2024-12-05 |
| Vitiligo, New Treatment and Serum s100B Baricitinib, oral mini pulse, Narrow Band UVB Treatment - Vitiligo, Generalized | Phase 2 / Phase 3 | Recruiting | South Valley University | 50 | 2024-10-02 | 2025-01-10 |
| Topical Ruxolitinib Evaluation in Immune-related Vitiligo-like Depigmentation Ruxolitinib Topical Cream - Immune-related Vitiligo-like-Depigmentation | Phase 2 | Active not recruiting | University of Zurich | 34 | 2024-07-25 | 2026-07-24 |
Showing 20 of 79. Sign in to see all of them.
Vitiligo (68) · Albinism (5) · Hermanski-Pudlak Syndrome (4) · Piebaldism (4) · Pigmentation Disorders (4) · Albinism, Oculocutaneous (3) · Eczema (2) · Gastrointestinal Stromal Tumors (2) · Platelet Storage Pool Deficiency (2) · Psoriasis (2) · Pulmonary Fibrosis (2) · Skin Diseases (2) · Alopecia Areata (1) · Autoimmune Diseases (1)
Skin and Connective Tissue Diseases (79) · Skin Diseases (77) · Pigmentation Disorders (75) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Skin Diseases, Genetic (12) · Amino Acid Metabolism, Inborn Errors (11) · Eye Diseases, Hereditary (11) · Nutritional and Metabolic Diseases (11) · Metabolic Diseases (10) · Metabolism, Inborn Errors (10) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (8) · Eye Diseases (7)
ruxolitinib (5) · Phototherapy (3) · Tacrolimus (3) · afamelanotide (3) · Imatinib Mesylate (2) · Latanoprost (2) · Ointments (2) · Percutaneous Collagen Induction (2) · Triamcinolone Acetonide (2) · apremilast (2) · pirfenidone (2) · 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide (1) · AMG-714 (1) · Acetylcysteine (1) · Adalimumab (1)
Centre Hospitalier Universitaire de Nice (10) · Incyte Corporation (4) · University of British Columbia (4) · University Hospital, Bordeaux (3) · Clinuvel Pharmaceuticals Limited (2) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Novartis Pharmaceuticals (2) · Sohag University (2) · South Valley University (2) · University of Colorado, Denver (2) · AbbVie (1) · Aclaris Therapeutics, Inc. (1) · Arcutis Biotherapeutics, Inc. (1) · Cairo University (1)
United States (34) · France (17) · Canada (12) · China (9) · Egypt (5) · Indonesia (3) · Australia (2) · Belgium (2) · Italy (2) · Japan (2) · Spain (2) · Argentina (1) · Denmark (1) · Finland (1) · Germany (1)
Harvey Lui, MD, FRCPC (4) · Passeron Thierry, PhD (3) · Ramadan Saleh, MD (2) · Ahmad Aleisa, MD (1) · Alexandra B Kimball, MD, MPH (1) · Alice Gottlieb, MD, PhD (1) · Babar Rao, MD (1) · Brett A. King, MD, PhD (1) · Brian P Brooks, M.D. (1) · Chuah Sai Yee, Ph (1) · David Berk, MD (1) · David Rosmarin, MD (1)
PMID 19627411, PMID 25545321, PMID 25902042, PMID 27329330, PMID 29617528, PMID 30674731, PMID 31758835, PMID 32004567, PMID 32653055, PMID 37840766, PMID 38873632, PMID 38946973, PMID 39475960, PMID 39737640, PMID 39841460, PMID 42046081, PMID 42869214
2025 (4), 2023 (2), 2009 (1), 2018 (1), R33AR077495 (1)